Literature DB >> 35373001

Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO.

Nestor Oliva-Damaso1, Andrew S Bomback2.   

Abstract

Entities:  

Keywords:  cyclophosphamide; glomerular and tubulointerstitial diseases; immunosuppressive agents; membranous glomerulonephritis; rituximab

Mesh：

Substances：

Year:  2021        PMID： 35373001      PMCID： PMC8785834          DOI： 10.34067/KID.0001842021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  13 in total

1.  Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

Authors:  Fernando C Fervenza; Gerald B Appel; Sean J Barbour; Brad H Rovin; Richard A Lafayette; Nabeel Aslam; Jonathan A Jefferson; Patrick E Gipson; Dana V Rizk; John R Sedor; James F Simon; Ellen T McCarthy; Paul Brenchley; Sanjeev Sethi; Carmen Avila-Casado; Heather Beanlands; John C Lieske; David Philibert; Tingting Li; Lesley F Thomas; Dolly F Green; Luis A Juncos; Lada Beara-Lasic; Samuel S Blumenthal; Amy N Sussman; Stephen B Erickson; Michelle Hladunewich; Pietro A Canetta; Lee A Hebert; Nelson Leung; Jay Radhakrishnan; Heather N Reich; Samir V Parikh; Debbie S Gipson; Dominic K Lee; Bruno R da Costa; Peter Jüni; Daniel C Cattran
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

Review 2.  Membranous Nephropathy: Approaches to Treatment.

Authors:  Andrew S Bomback; Fernando C Fervenza
Journal:  Am J Nephrol       Date:  2018-05-31       Impact factor: 3.754

Review 3.  Membranous Nephropathy: Core Curriculum 2021.

Authors:  Loulwa Alsharhan; Laurence H Beck
Journal:  Am J Kidney Dis       Date:  2021-01-21       Impact factor: 8.860

4.  Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.

Authors:  K Dahan; C Johannet; E Esteve; E Plaisier; H Debiec; P Ronco
Journal:  Kidney Int       Date:  2019-01       Impact factor: 10.612

5.  The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.

Authors:  Gema Fernández-Juárez; Jorge Rojas-Rivera; Anne-Els van de Logt; Joana Justino; Angel Sevillano; Fernando Caravaca-Fontán; Ana Ávila; Cristina Rabasco; Virginia Cabello; Alfonso Varela; Montserrat Díez; Guillermo Martín-Reyes; Marian Goicoechea Diezhandino; Luis F Quintana; Irene Agraz; Juan Ramón Gómez-Martino; Mercedes Cao; Antolina Rodríguez-Moreno; Begoña Rivas; Cristina Galeano; Jose Bonet; Ana Romera; Amir Shabaka; Emmanuelle Plaisier; Mario Espinosa; Jesus Egido; Alfonso Segarra; Gérard Lambeau; Pierre Ronco; Jack Wetzels; Manuel Praga
Journal:  Kidney Int       Date:  2020-11-07       Impact factor: 10.612

6.  Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Authors:  Fernando C Fervenza; Roshini S Abraham; Stephen B Erickson; Maria Valentina Irazabal; Alfonso Eirin; Ulrich Specks; Patrick H Nachman; Eric J Bergstralh; Nelson Leung; Fernando G Cosio; Marie C Hogan; John J Dillon; LaTonya J Hickson; Xujian Li; Daniel C Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-12       Impact factor: 8.237

7.  A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini; B Cesana; F Locatelli; S Pasquali; M Sasdelli; B Redaelli; C Grassi; C Pozzi
Journal:  Kidney Int       Date:  1995-11       Impact factor: 10.612

8.  Rituximab for idiopathic membranous nephropathy.

Authors:  Giuseppe Remuzzi; Carlos Chiurchiu; Mauro Abbate; Verusca Brusegan; Mario Bontempelli; Piero Ruggenenti
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

9.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

10.  Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Authors:  Francesco Scolari; Elisa Delbarba; Domenico Santoro; Loreto Gesualdo; Antonello Pani; Nadia Dallera; Laila-Yasmin Mani; Marisa Santostefano; Sandro Feriozzi; Marco Quaglia; Giuliano Boscutti; Angelo Ferrantelli; Carmelita Marcantoni; Patrizia Passerini; Riccardo Magistroni; Federico Alberici; Gian Marco Ghiggeri; Claudio Ponticelli; Pietro Ravani
Journal:  J Am Soc Nephrol       Date:  2021-03-01       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.